| 研究課題/領域番号 |
22K19291
|
|---|
| 研究種目 |
挑戦的研究(萌芽)
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
中区分43:分子レベルから細胞レベルの生物学およびその関連分野
|
|---|
| 研究機関 | 京都大学 |
|---|
研究代表者 |
|
|---|
| 研究分担者 |
Packwood Daniel 京都大学, 高等研究院, 講師 (40640884)
|
|---|
| 研究期間 (年度) |
2022-06-30 – 2024-03-31
|
| 研究課題ステータス |
交付 (2022年度)
|
| 配分額 *注記 |
6,370千円 (直接経費: 4,900千円、間接経費: 1,470千円)
2023年度: 2,990千円 (直接経費: 2,300千円、間接経費: 690千円)
2022年度: 3,380千円 (直接経費: 2,600千円、間接経費: 780千円)
|
|---|
| キーワード | Nanopore / Direct RNA sequencing / RNA-protein interactions / Chemical probe / Machine learning / ナノポアシークエンシング / リボソーム / RNA-たんぱく質相互作用 / ケミカルプローブ / バイオインフォマティクス |
|---|
| 研究開始時の研究の概要 |
本研究は、学際的なアプローチを使用して、RNP-BI-NANO-Seqと呼ばれる迅速に適応できるシーケンス技術を開発することを目的としている。これにより、癌のリボソームにおけるRNA-タンパク質相互作用を調べる既存の方法における欠点を克服することが可能である。癌だけでなく他の多くの病気でもリボソームの機能不全は見られる。これら疾患に対する既存の薬剤の多く はリボソームを標的にしており、結果として得られたデータセットは、新しい創薬可能な RNA構造を明らかにし、新しい創薬に役立つ。
|
| 研究実績の概要 |
In this fiscal year, we have successfully demonstrated the proof-of-concept (POC) studies to verify that chemical probes can be harnessed in nanopore direct RNA sequencing (dRNA-Seq) platform and can aid in assessing RNA modifications. We published (ACS Chem. Biol. 2022) the part of our results to show that the chemical probe (acrylonitrile) could selectively react with the inosine modification and create a signature mismatch error to deduce the presence of actual inosine modifications. We also deduced the stoichiometry of inosine modification through deviation in signal intensity and trace value. Our methods showed that Adenosine to inosine (A-I) editing could be accurately identified using mismatch error with an accuracy greater than 80% using synthetic RNA and support vector machine learning. Furthermore, we have substituted the need for such a null data set and demonstrated that the acrylonitrile’s selective reactivity could facilitate distinguishing signature mismatch errors from noise. We also modified a `nanoRMS workflow` and showed that chemical probes efficiently alter trace value and signal intensity. We also summarized how machine-learning tools could aid the discovery of natural product-derived small molecules that can serve as targeted therapeutics and probes. Furthermore, the nano-bio interaction of the functionalized quantum dots, which is expected to harbor the bi-functional probe to decipher RNA-protein interaction, was tested using the in vitro and in vivo models. These results form an ideal platform for the integrated approach to mapping RNA dynamics.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
1: 当初の計画以上に進展している
理由
We have successfully integrated cutting-edge techniques like artificial intelligence (AI), nanopore sequencing, and nucleic acid-based small targeted small molecules to apply to developing a direct RNA sequencing (dRNA-Seq) methodology. Our dRNA-Seq on the mouse brain revealed bonafide Adenosine to inosine (A-I sites) through mismatch errors. However, the unbiased de novo capturing of A-I modifications using chemical probe-induced signal difference was hindered by lower coverage. Nevertheless, we addressed the issue of low coverage associated with the dRNA-Seq by developing Nano ICE-Seq, efficiently capt A-I sites not sampled by dRNA-Seq. The “quick to adapt” Nano ICE-Seq with 30 h of runtime (experiment to analysis) could efficiently probe clinically relevant differential A-I sites as diagnostic or prognostic markers. We published two original articles and two review papers. Web portals and oxford nanopore`s social media sites also highlighted our work. Because A-I differential editing is implicated in inflammatory skin disorders and Osteoarthritis, we also extended our approach through international collaborations. Through the JSPS exchange programs, Dr. Reihane Ziadlou from the University of Zurich and Dr. Valentina Basoli from AO Research Institute visited us for three months. In exchange, Dr. Namasivayam visited and gave an invited lecture at the University of Zurich`s skintegrity mini-symposium. Also, our team member Katsuhiko Abe visited AO Research Institute for six months to accelerate the collaboration and cover more new research areas this year.
|
| 今後の研究の推進方策 |
Encouraged by the results obtained in the last fiscal year, we aim to develop a new type of bifunctional probe using a selective 2'-hydroxyl acylating agent (SHAPE) that is analyzed by primer extension. The plan this year is as follows,
1) Improve the design of the chemical probes that interact with RNA and amino acids by functionalizing them on the biodegradable carbon dots.
2) We encountered a bottleneck of a size limitation of the chemical probe, and there needs to be a trade-off between the size and selective reactivity and small molecule probes need to be of optimal size to enter the one nm-sized bacterial nanopore. To overcome this issue, we devised an approach to create a new protocol and device by ourselves. Because modifying the bacterial pores is laborious and not precise, we plan to perform a one-pot synthesis of DNA origami to create programmable nanopores of varied sizes (5-8 nm) and shapes (two or three constrictions).
3) We plan to optimize our device in an in vitro CRISPR system before transferring it to evaluate its efficacy in an in vitro cell line model. We will use human dermal fibroblasts to probe inflammatory skin disorders and mesenchymal stem cells to probe osteoarthritis.
|
